Glenmark Pharmaceuticals’ Swiss subsidiary -- Glenmark Specialty S.A., has received marketing approval from the Ministry of Health of the Russian Federation for its innovative Ryaltris Nasal Spray - a novel fixed-dose combination nasal spray. This paves the way for commercialization of Ryaltris in Russia which is expected to be made available to patients in the country in Q1 FY 2021-22.
Ryaltris (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg), is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. Ryaltris relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
